Stivarga 40 MG tablet 21S
Ended Awarded
- Contract number
- SPE2DR26FKNL1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $47,144
Award facts
- Contract value 100% obligated
- $47,143.89 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $47,143.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stivarga 40 mg tablets (21-count units). The delivery order, awarded on November 17, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the vendor competed on an unrestricted basis. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy that was awarded to the company on November 13, 2025, with a ceiling value of $499,999,999 and a completion date of December 31, 2036.
The PPV-G GEN V contract positions DMS Pharmaceutical Group as a critical regional prime vendor contractor authorized to fulfill diverse pharmaceutical supply requirements, including branded and generic prescription medications, biologics, and medical consumables, for Department of Defense healthcare facilities worldwide. The company's SAM registration since 2001 and demonstrated track record of substantial federal contracting activity underscore its capability to serve as a reliable supplier within the military medical supply chain. As the sole identified prime contractor on this delivery order with no subcontractors involved, DMS Pharmaceutical Group maintains direct responsibility for fulfilling this oncology pharmaceutical requirement to support DOD medical operations.
Quick answers
Who was awarded contract SPE2DR26FKNL1?
SPE2DR26FKNL1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FKNL1 worth?
The government has obligated $47,144 on SPE2DR26FKNL1.
Is contract SPE2DR26FKNL1 an order under another contract?
Yes. SPE2DR26FKNL1 is a delivery order under SPE2DR25D9314, an indefinite delivery contract.
Was contract SPE2DR26FKNL1 competed?
The extent of competition for SPE2DR26FKNL1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award